Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Search
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Atrovent®
Prevention and treatment of shortness of breath in patients with chronic obstructive pulmonary disease (COPD) and mild to moderate bronchial asthma in adulthood and childhood as a supplement to beta-agonists in cases of acute asthma.
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Heart Failure
Heart Failure
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Semintra®
4mg/ml – Management of chronic kidney disease (CKD) in cats: for reduction of proteinuria associated with CKD in cats. 10mg/ml – Hypertension: indicated for the treatment (EU)/control (US) of feline systemic hypertension.
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Ingelvac CircoFLEX
For the active immunisation of pigs over the age of two weeks against porcine circovirus type 2 to reduce mortality, clinical signs – including weight loss – and lesions in lymphoid tissues associated with porcine circovirus diseases (PCVD).
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Pulmonary Fibrosis
Pulmonary Fibrosis
Our Responsibility
Human Health Our Responsibility
Patient Centricity
Patient Centricity
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction